A big part of Washington, D.C.’s plan to get its HIV rate down is to get more uninfected people on PrEP, a two-medicine combination pill that’s sold under the brand name Truvada.
When taken daily by people who are at high risk for contracting HIV via sex or shared needles with someone who is infected, this pre-exposure prophylaxis, or PrEP, can cut the risk of HIV infection by 92 percent, studies show.
PrEP has been around for years now, but only a small portion of those at high risk for HIV infection use it, partly because many still don’t know it exists. The medicine is also quite expensive, priced at $1,600 for a month’s supply. It is usually covered by insurance, including Medicaid.